Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice.
暂无分享,去创建一个
Robert Langer | Ana Jaklenec | Giovanni Traverso | Gregory Y. Lauwers | Daniel Minahan | Cody Cleveland | Daniel G. Anderson | Scott B. Snapper | R. Langer | S. Snapper | G. Traverso | C. Schoellhammer | M. Oberli | Cody Cleveland | G. Lauwers | D. Minahan | A. Jaklenec | Yiyun Chen | Jeremy A. Goettel | Matthias A. Oberli | Carl M. Schoellhammer | June Y. Park | J. Goettel | J. Y. Park | Yiyun Chen | Daniel Minahan
[1] Giovanni Traverso,et al. Low-frequency ultrasound for drug delivery in the gastrointestinal tract , 2016, Expert opinion on drug delivery.
[2] R. Klopfleisch,et al. Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[3] Mohammad Ariful Islam,et al. Biomaterials for mRNA delivery. , 2015, Biomaterials science.
[4] Daniel G. Anderson,et al. Ultrasound-mediated gastrointestinal drug delivery , 2015, Science Translational Medicine.
[5] T. Murdoch,et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.
[6] Maria Fichera,et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. , 2015, The New England journal of medicine.
[7] Samir Mitragotri,et al. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.
[8] Daniel G. Anderson,et al. Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.
[9] L. Fändriks,et al. Surface area of the digestive tract – revisited , 2014, Scandinavian journal of gastroenterology.
[10] Markus F. Neurath,et al. Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.
[11] Robert Langer,et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.
[12] Robert Langer,et al. A vector-free microfluidic platform for intracellular delivery , 2013, Proceedings of the National Academy of Sciences.
[13] Hollis G. Potter,et al. Author Manuscript , 2013 .
[14] T. Schlake,et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection , 2012, Nature Biotechnology.
[15] Laura M Ensign,et al. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.
[16] P. Uzor,et al. Transdermal Drug Delivery , 2012 .
[17] Gaurav Sahay,et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. , 2012, Journal of the American Chemical Society.
[18] E. Szigethy,et al. Inflammatory bowel disease. , 2011, Pediatric clinics of North America.
[19] R. Langer,et al. Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs , 2010, Expert opinion on drug delivery.
[20] Didier Merlin,et al. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. , 2010, Nature materials.
[21] Vincent M Rotello,et al. Intracellular delivery of a membrane-impermeable enzyme in active form using functionalized gold nanoparticles. , 2010, Journal of the American Chemical Society.
[22] K. G. Rajeev,et al. Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.
[23] L. Hale,et al. Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription , 2008, Journal of Inflammation.
[24] D. Teitelbaum,et al. Colostomy: formation and closure , 2006 .
[25] Mark R Prausnitz,et al. Mechanism of intracellular delivery by acoustic cavitation. , 2006, Ultrasound in medicine & biology.
[26] B. Baker,et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.
[27] G. Devi,et al. siRNA-based approaches in cancer therapy , 2006, Cancer Gene Therapy.
[28] Thierry Bettinger,et al. Plasma membrane poration induced by ultrasound exposure: implication for drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[29] S. V. van Deventer,et al. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis , 2004, Gut.
[30] A. Gewirtz,et al. Alicaforsen. Isis Pharmaceuticals. , 2001, Current opinion in investigational drugs.
[31] T. Macdonald,et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.
[32] C. Fiocchi,et al. TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. , 2001, The Journal of clinical investigation.
[33] C. Heldin,et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.
[34] C. Heldin,et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. , 1997, Nature.
[35] H. Cooper,et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[36] D. Podolsky,et al. Inflammatory bowel disease (1) , 1991, The New England journal of medicine.
[37] R E Apfel,et al. Thresholds for transient cavitation produced by pulsed ultrasound in a controlled nuclei environment. , 1989, The Journal of the Acoustical Society of America.
[38] G PLACITELLI,et al. [Ulcerative colitis]. , 1958, La Riforma medica.
[39] C. FordAlexander,et al. ULCERATIVE colitis. , 1997, Journal of the American Medical Association.